Prednisolone With Clomiphene Citrate in Ovulation Induction in Clomiphene Citrate-Resistant Polycystic Ovary Syndrome

Dr Suhaila Fadhil Al-Shaikh
(FABMS. OG), (FIBMS.OG)
Lecturer/ college of medicine/ Babylon univ

INTRODUCTION:

It has been suggested recently that, in some quarters, IVF be offered as 1st-line therapy to all infertile couples, regardless of the type of infertility. Hence, the time was thought right to scrutinize the results and complications of ovulation induction for anovulatory infertile couples. In addition to examining the outcome of conventional treatment with gonadotrophins and clomiphene citrate, special attention has been paid to the suggested improvement of results by taking into account the influence of obesity and the use of a low-dose gonadotrophin protocol. The possible contribution of more recent additions to the armamentarium such as insulin sensitizers and aromatase inhibitors, are promising. Attention has been given to the prevention and treatment of ovarian hyperstimulation syndrome. The use of intra-uterine insemination (IUI) as an adjuvant to induction of ovulation and controlled ovarian hyperstimulation (COH) is examined. The very firm conclusion has been reached that, taking into account efficiency, complication rate and cost of treatment, at this stage, women with hypogonadotrophic hypogonadism or polycystic ovary syndrome should be offered accepted methods of ovulation induction and that couples with `unexplained' or `multifactorial subfertility' should still be exposed to COH with IUI and only after the failure of these therapies, be offered IVF (1).

Clomiphene citrate (CC) is the traditional first-line treatment for chronic anovulation that characterizes polycystic ovary syndrome (PCOS) (2).

CC is accumulated in the body with low clearance rate and long half-life (5 days). Significant plasma concentrations of the active isomer of CC can be detected up to 6 weeks after administration. However, 20–25% of PCOS women fail to ovulate with incremental doses of CC. In addition, clinical data revealed a discrepancy between ovulation rates (75–80%) and conception rates (30–40%) during CC treatment (3).

The use of corticosteroid for the treatment of ovulatory dysfunction was first reported in 1953 by Jones et al. and Greenblatt (1). Parsanezhad et al. (2002) had reported the novel use of the dexamethazone (DEX) (high dose, short course) for inducing ovulation in anovulatory women with PCOS and normal dehydroepiandrosterone sulphate (DHEAS) (4). Dexamethazone therapy during the follicular phase has been described without any side effects or serious sequelae (5). Our objective was to evaluate the efficacy of adding prednisolone to CC in CC resistant PCOS in induction of ovulation.
Materials and methods:

Forty three infertile women their age range between (19 – 40 ) years were included from the patients attending the infertility clinic of Babil Hospital between April 2008 and October 2009. Patients were diagnosed as having PCOS according to the Rotterdam criteria for diagnosis of PCOS (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004) (6). No patient showed hyperprolactinaemia, clinical evidence of hypercorticism or thyroid dysfunction. All patients had previously received CC 100 mg / day for five days and diagnosed as having CC resistance (failure of ovulation after three cycles of CC. Our inclusion criteria were: (i) age between 17 and 42 years; (ii) period of infertility >1 year; (iii) no treatment was taken during the last 2-3 months prior to the prednisolone co-treatment.

Exclusion criteria were infertility factor other than anovulation like tubal factor or of pelvic surgery or male factors. Hirsutism was diagnosed when the Ferriman and Gallwey score was >8.

Patients were divided into 2 groups 1st group (31 patients) received CC and co-treatment with prednisolone and the 2nd group (12 patients) received higher dose of CC 150 mg / day

Amenorrheic patients began treatment with induction of menstruation using Progesterone injection (100 mg). Ultrasonography was performed using a transvaginal transducer (6.5 MHz, endovaginal probe). On day 2, each patient underwent a baseline ultrasonographic examination. Clomiphene citrate, 100 mg for the 1st group and 150 mg for the 2nd group, was given from day 2 until day 6. In addition to the CC each patient received prednisolone 10 mg/day orally, in two divided doses from day 2- 12 of the cycle in the 1st group. Transvaginal ultrasound examination was done 2 days after the end of CC and every other day according to the follicular size. HCG 10 000 U (Pregnyl) was given when at least one follicle measured 18 mm. Timed intercourse was advised 24–36 h after HCG injection. pregnancy was diagnosed by a positive pregnancy test and then when a gestational sac was detected on U/S. Each participant had only two treatment cycles.

Outcome measures
The primary outcome was the ovulation rate in the treatment cycle. Secondary outcome were the endometrial thickness and the pregnancy rate.

Statistical analysis
Data where collected and described by using number, percentage, minimum and maximum and mean +/- standard deviation, association between variables where measured by using t-test, chi square when appropriate. A P-level of <0.05 was considered statistically significant.
Results

As summarized in Table no. 1 there were no statistically significant differences between both groups regarding; age, duration of infertility, FSH and LH levels.

In table no. 2 it can be seen that there is no statistically significant difference between the two groups regarding the type of infertility, menstrual cycle pattern, hirsutism and PCO picture by U/S.

In table no. 3 it is evident that there is significantly higher rates of ovulation and pregnancy were seen in the 1st group as the endometrial thickness so.

In table no. 4 the distribution of the patients in relation to response to treatment is shown.
Prednisolone was very well tolerated as no patients complained of any side effect.

Table no. 1: Patients characteristics regarding the mean+/-SD of the age, duration of infertility, FSH and LH levels:

<table>
<thead>
<tr>
<th>characters</th>
<th>1st group N(Mean +/- SD)</th>
<th>2nd group N(Mean +/- SD)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>31(27.77 +/- 6.41)</td>
<td>12(29.23 +/- 6.21)</td>
<td>NS</td>
</tr>
<tr>
<td>Duration of infertility</td>
<td>31(4.34 +/- 1.91)</td>
<td>12(4.31 +/- 1.6)</td>
<td>NS</td>
</tr>
<tr>
<td>FSH mIU/ml</td>
<td>31(8.16 +/- 4.32)</td>
<td>12(6.78 +/- 4.65)</td>
<td>NS</td>
</tr>
<tr>
<td>LH mIU/ml</td>
<td>31(8.74 +/- 4.81)</td>
<td>12(8.16 +/- 4.32)</td>
<td>NS</td>
</tr>
</tbody>
</table>
Table no. 2: total no. of the patients and (%) of the type of Infertility, menstrual cycle history, hirsutism and PCO picture by U/S

<table>
<thead>
<tr>
<th>Type of infertility</th>
<th>Character</th>
<th>Total number (%)</th>
<th>1&lt;sup&gt;st&lt;/sup&gt; group N (%)</th>
<th>2&lt;sup&gt;nd&lt;/sup&gt; group N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>primary</td>
<td>21(48.84%)</td>
<td>15 (48.39%)</td>
<td>6 (50%)</td>
</tr>
<tr>
<td></td>
<td>secondary</td>
<td>22(51.16%)</td>
<td>16 (51.6%)</td>
<td>6 (50%)</td>
</tr>
<tr>
<td>Menstrual cycle</td>
<td>oligomenorrhoea</td>
<td>27(62.79%)</td>
<td>19 (61.29%)</td>
<td>8 (66.66%)</td>
</tr>
<tr>
<td></td>
<td>amenorrhoea</td>
<td>6(13.95%)</td>
<td>4 (12.9%)</td>
<td>2(16.67%)</td>
</tr>
<tr>
<td></td>
<td>Regular</td>
<td>10(23.26%)</td>
<td>8 (25.81%)</td>
<td>2 (16.67%)</td>
</tr>
<tr>
<td></td>
<td>Hirsutism</td>
<td>12(27.91%)</td>
<td>8 (25.8%)</td>
<td>4 (33.3%)</td>
</tr>
<tr>
<td></td>
<td>PCO (U/S)</td>
<td>36(83.72%)</td>
<td>26 (83.87%)</td>
<td>10 (83.33%)</td>
</tr>
</tbody>
</table>

Table no. 3: Outcome of treatment in both groups 1<sup>st</sup> group(clomiphene + prednisolone) and the 2<sup>nd</sup> group (clomiphene only)

<table>
<thead>
<tr>
<th>Response to treatment</th>
<th>1&lt;sup&gt;st&lt;/sup&gt; group N=31</th>
<th>2&lt;sup&gt;nd&lt;/sup&gt; group N=12</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ovulation</td>
<td>23 (74.19%)</td>
<td>2 (16.66%)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Endometrial thickness (mm)</td>
<td>8.82 +/- 1.49</td>
<td>7.03 +/- 0.74</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>pregnancy</td>
<td>17 (54.84%)</td>
<td>1 (8.33%)</td>
<td>&lt; 0.05</td>
</tr>
</tbody>
</table>
Table no.4: Ovulation and pregnancy in the subgroups (with primary and secondary infertility)

<table>
<thead>
<tr>
<th>Patients subgroups</th>
<th>Response to R/</th>
<th>Ovulation</th>
<th>pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st group</td>
<td>Primary infertility (15)</td>
<td>11 (73.33%)</td>
<td>6 (40%)</td>
</tr>
<tr>
<td></td>
<td>Secondary infertility (16)</td>
<td>12 (75%)</td>
<td>11 (68.75%)</td>
</tr>
<tr>
<td>2nd group</td>
<td>Primary infertility (6)</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td></td>
<td>Secondary infertility (6)</td>
<td>2 (33.33%)</td>
<td>1 (16.66%)</td>
</tr>
</tbody>
</table>

Discussion:

Parsanezhad et al. (2002) had reported the novel use of the Dexamethazone (high dose, short course) for inducing ovulation in anovulatory women with PCOS and normal androgen levels. Dexamethazone therapy during the follicular phase has been described without any side effects or serious sequelae (4,5).

Azziz et al. (1999) found that there were no differences in ovulatory response to DEX therapy between women with and without androgen excess (1).

On the other hand, Daly et al. (1984) reported that the effect of steroids was largest in women with raised androgen levels (6). The recent systematic review of the Cochrane library reported that the use of steroids like prednisolone or Dexamethazone as an adjunct to CC appears promising (7).

In this study, significantly higher rate of ovulation was reported in the prednisolone group 23(74.19%) vs 2 (16.66%), and in the Clomiphene plus prednisolone treatment group there is a significant improvement in the pregnancy rate when compared to CC alone 17 (54.84%) vs 1 (8.33%) respectively, These results are in agreement with the results of Parsanezhad et al. (2002) (4).

There are a number of potential mechanisms by which steroids may affect ovarian function. Prednisolone acts directly on the pituitary gland to suppress the action of estradiol, which may be involved in the process of induction of ovulation by glucocorticoid–clomiphene treatment (8).
prednisolone enhances the FSH-stimulated follicular steroid production. The synergism of glucocorticoids with FSH in follicular progesterone production and its inhibition by transforming growth factor-β (TGF-β) indicate that glucocorticoid and TGF-β interaction may be necessary for granulosa cell differentiation as follicle matures through pre-antral stages (9).

The pregnancy rate in the 1st group were significantly higher than in the 2nd group. The endometrium was of adequate thickness to allow implantation. The adverse endometrial effect seen with CC, which is augmented by the relatively long half-life of CC (5 days), is not seen in the 1st group. This result is consistent with the results of other studies (4, 5). They compared the effects of Dexamethasone and CC on the endometrium.

Immunosuppression, leading to a favourable endometrial environment, was the rationale behind the administration of high-dose glucocorticoid from embryo transfer onwards, and higher implantation rates have been observed (10). Prednisolone predominantly influenced ovarian response, and a major endometrial effect is unlikely with the low dose used although a trend towards higher embryo implantation was observed.

In this study, prednisolone use during the follicular phase resulted in a high rate of ovulation (74.19%) with a pregnancy rate of 54.84%. All pregnancies were single. Parsanezhad et al. (2002) reported a higher ovulation rate (88%) (4). This may be explained by the higher dose of CC (200 mg/day) given in their study. Compared to other methods of ovulation induction, the multiple pregnancy rates is approximately 10% with CC, almost entirely twins (11), 15–25% with gonadotrophins (12) and about 2% with laparoscopic ovarian drilling (13). Comparing prednisolone with other medical methods of ovulation induction in cases of CC resistant PCOS, it is not as expensive as gonadotrophins and does not need intensive monitoring during and after treatment.

Thus, we can give prednisolone or dexamethazone to all patients with CC resistance, as its efficacy is not limited to a specific abnormality, and it can be used whatever the BM (14).

Some authors used low-dose DEX (0.5 mg/day) for 1 month (5; 6; 15; 16; 17; 18). Ovulation rates ranged from 55 to 80%, and pregnancy rates ranged from 8.3 to 49%. The high-dose, short-course regimen is more convenient to the patient with higher ovulation (75–88%) and pregnancy rates (40–40.5%) according to the results of Parsanezhad et al. (4). DEX 2.0 mg from day 2 to day 12 of the cycle would seem more appropriate than 0.5 mg until further data on 0.5 mg are available (7). Further studies comparing the two regimens are required.
**Conclusion:**

Induction of ovulation by adding prednisolone or dexamethazone to CC in CC-resistant PCOS is associated with no adverse anti-estrogenic effect on the endometrium and higher ovulation and pregnancy rates in a significant number of patients.

Induction with steroids appears to be independent on age, period of infertility. Addition of prednisolone or Dexamethazone to CC is an effective, inexpensive and safe method for stimulating follicular development in CC-resistant PCOS and may be tried before gonadotrophins and laparoscopic ovarian drilling.

**References:**

1. Azziz R, Black V, Knochenhauer E, Hines G and Boots L. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level. J Clin Endocrinol Metab: (1999); 84; pp 946–950.


بردنيزولون مع كلوميفين ستريت في تخفيف التببض في متلازمة تكيس المبايض المقاومة للكلوميفين ستريت

الخليصة:


في المجموعة الأولى أعطيت المريضات كلوميفين 100 ملغم (من اليوم الثاني إلى السادس للدورة الشهرية مع بردنيزولون 10 ملغم من اليوم 2 – 12 وامام المجموعة الثانية فاعطيت كلوميفين 150 ملغم من اليوم 2 – 6 من الدورة.

المخرجات التي اعتمدت لنجاح الطريقة العلاجية كانت كالتالي:

أولا نسبة حدوث التببض
ثانيا سمك البطانة الرحمية ونسبة حدوث الحمل

كان حدوث التببض في المجموعة الأولى 44.19 %، أما في المجموعة الثانية كان 16.16 % ونسبة حدوث الحمل كانت 34.54 %، و في المجموعة الثانية كانت 33.12 %.

الاستنتاج:

من هذه النتائج يتضح أن الكلوميفين ستريت مع البردنيزولون يصبح أن يكون خيارا جيدا لعلاج الحالات المقاومة للكلوميفين ستريت لإن علاج غير مكلف الثمن ذو نتائج جيدة قبل اللجوء إلى الطرق الأخرى التي يمكن استخدامها في هكذا حالات مثل استخدام الهرمونات المنشطة (FSH) أو طريقة كي الآكياس المبيضية عن طريق الناظور (ovarian drilling).